Today: 29 April 2026
Centrus Energy (LEU) stock price jumps into long weekend as nuclear fuel trade stays in focus

Centrus Energy (LEU) stock price jumps into long weekend as nuclear fuel trade stays in focus

NEW YORK, Jan 17, 2026, 08:24 (EST) — Market closed.

  • Centrus Energy jumped in the final U.S. trading session, riding a wave of gains across nuclear-related stocks.
  • Focus remained on government-backed reactor and fuel supply plans after a new U.S.-Slovakia nuclear agreement was announced.
  • U.S. markets reopen Tuesday, with investors focused on follow-through and the upcoming earnings season.

Centrus Energy Corp (LEU) shares climbed 8.2% on Friday, closing at $331.03. Trading volume hit roughly 1.6 million shares, with prices swinging between $298.10 and $333.30 during the session.

The bounce is significant since Centrus operates in a crucial segment of the nuclear supply chain: uranium enrichment. This process raises the uranium concentration for reactor fuel—a bottleneck investors are keenly watching.

Friday brought a flurry of nuclear news. The U.S. inked a civil nuclear power deal with Slovakia, aiming to cut ties to Russian-designed reactors. The agreement centers on a 1,200-megawatt unit designed in the U.S., developed by Westinghouse, which is owned by Cameco and Brookfield Asset Management. “Today’s civil nuclear agreement reflects our shared commitment to strengthening European energy security and sovereignty for decades to come,” said U.S. Energy Secretary Chris Wright. Reuters

Shares in other nuclear-related companies moved higher alongside it. Cameco rose 3.2% on Friday, BWX Technologies was up 2.2%, and NuScale Power jumped 7.0%.

Centrus has grabbed significant attention after the U.S. Department of Energy picked it earlier this month for a $900 million task order to boost enrichment capacity at its Piketon, Ohio, facility. The move aligns with Washington’s push to reduce dependence on Russian sources. This award is part of a larger $2.7 billion package targeting enrichment projects, aiming to ramp up production of High-Assay, Low-Enriched Uranium (HALEU)—a fuel type used in some advanced reactors—while also expanding output of the low-enriched uranium (LEU) that powers current reactors. “This award will catalyze additional private investment,” CEO Amir Vexler said. Centrus also highlighted $2.3 billion in LEU purchase commitments, with the first new capacity slated to come online in 2029. Reuters

The key now is whether Friday’s jump was just a one-off squeeze or the beginning of a sustained rally. Traders are eyeing new details on how fast fresh enrichment capacity can be funded and constructed, and who will lock in long-term supply contracts.

The downside scenario is straightforward. Enrichment projects take years, face strict regulation, and depend heavily on federal contracts and political winds. Any delays, changes in priorities, or weaker demand for advanced-reactor fuel could quickly sour sentiment.

U.S. markets were closed Monday for Martin Luther King Jr. Day, putting the spotlight on Tuesday, Jan. 20, when trading restarts. Traders caution that volatility often rises after January’s monthly options expiration.

Investors are also watching upcoming earnings reports. Centrus hasn’t set an official date yet, but Zacks Investment Research points to Feb. 5 as the likely earnings release. Still, the market might get an early sense of Friday’s momentum well before that.

Stock Market Today

  • Humana Shares Climb 5% After Strong Q1 Earnings Beat
    April 29, 2026, 5:34 PM EDT. Humana Inc (HUM) stock surged 5% after reporting a robust first quarter with revenue rising 23% and adjusted earnings per share surpassing expectations. The health insurer reaffirmed its adjusted full-year profit forecast of at least $9 per share but lowered its nonadjusted earnings estimate to $8.36 from $8.89. Charges linked to its multiyear transformation program, aimed at realigning costs and operations amid evolving market conditions, were disclosed. Despite sector headwinds from rising medical and pharmaceutical costs and tighter Medicare Advantage regulations impacting profits, Humana's strong quarterly results sparked investor optimism. Year to date, shares remain down about 8%.

Latest article

Nebius Stock Jumps as Meta’s AI Spending Reset Puts $27 Billion Deal in Focus

Nebius Stock Jumps as Meta’s AI Spending Reset Puts $27 Billion Deal in Focus

29 April 2026
Nebius Group N.V. shares rose 5.3% to $142.73 Wednesday as Meta Platforms raised its 2026 capital spending forecast by up to $10 billion, citing higher data center costs. Nebius has a contract to supply Meta with up to $27 billion in AI cloud capacity. Fourth-quarter 2025 revenue jumped 547% to $227.7 million, but the company reported a net loss of $249.6 million.
Phillips 66 Stock Jumps as Surprise Profit Shows Refining Margins Are Back in Focus

Phillips 66 Stock Jumps as Surprise Profit Shows Refining Margins Are Back in Focus

29 April 2026
Phillips 66 reported an adjusted first-quarter profit of $200 million, or 49 cents per share, beating analyst forecasts of a loss. Strong refining margins and 95% plant utilization offset $839 million in hedge-related losses. Shares rose over 6% after the results. The company also completed its acquisition of Lindsey Oil Refinery assets in the UK.
Extreme Networks Stock Jumps as Q3 Earnings Beat Puts Cisco, HPE Rivals in Focus

Extreme Networks Stock Jumps as Q3 Earnings Beat Puts Cisco, HPE Rivals in Focus

29 April 2026
Extreme Networks shares surged 28% after reporting fiscal Q3 revenue of $316.9 million, up 11%, and non-GAAP earnings of 26 cents per share, both above estimates. The company forecast Q4 revenue of $330–$335 million, topping FactSet’s $326.9 million estimate. SaaS annual recurring revenue rose 28.6% to $236.4 million. Net income climbed to $10.6 million from $3.5 million a year earlier.
AST SpaceMobile stock spikes on $151 billion SHIELD defense pool nod — what to watch next week
Previous Story

AST SpaceMobile stock spikes on $151 billion SHIELD defense pool nod — what to watch next week

Eli Lilly stock price in focus as FDA slips obesity pill deadline — what to watch in LLY next week
Next Story

Eli Lilly stock price in focus as FDA slips obesity pill deadline — what to watch in LLY next week

Go toTop